VPA treatment seems to induce the down-regulation of Notch activity via the suppression of its HES family bHLH transcription factor 1 (HES1) target gene, with augmenting p21 and p63 tumor suppressors in hepatocellular carcinoma cells [37]. The gene discussed is RRBP1; the disease is neoplasm.